Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice
- PMID: 2498959
- DOI: 10.1007/BF00442002
Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice
Abstract
The adenosine agonists 5'-N-ethylcarboxamideadenosine (NECA), 2-chloroadenosine (2-CLA), N6-cyclohexyladenosine (CHA), N6-cyclopentyladenosine (CPA), 2-(phenylamino)adenosine (CV-1808) and R and S isomers of N6-phenylisopropyladenosine (R-PIA and S-PIA) decreased spontaneous locomotor activity in mice and, except for CPA, did so at doses that did not impair motor coordination, a profile shared by dopamine antagonists. CV-1808, the only agent with higher affinity for A2 as compared with A1 adenosine receptors, displayed the largest separation between locomotor inhibitory and ataxic potency. Like dopamine antagonists, NECA and CV-1808 also decreased hyperactivity caused by d--amphetamine at doses that did not cause ataxia whereas A1-selective adenosine agonists reduced amphetamine's effects only at ataxic doses. Unlike dopamine antagonists, adenosine agonists inhibited apomorphine-induced cage climbing only at doses that caused ataxia. Involvement of central adenosine receptors in these effects was suggested by the significant correlation obtained between potency for locomotor inhibition after IP and ICV administration. Affinity for A1 but not A2 adenosine receptors was significantly correlated with potency for inducing ataxia. These results suggest that the behavioral profile of adenosine agonists in mice is related to their affinity for A1 and A2 adenosine receptors and indicate that adenosine agonists produce certain behavioral effects that are similar to those seen with dopamine antagonists.
Similar articles
-
Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.Pol J Pharmacol. 2002 Jul-Aug;54(4):359-66. Pol J Pharmacol. 2002. PMID: 12523489
-
Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.Mol Pharmacol. 1986 Apr;29(4):331-46. Mol Pharmacol. 1986. PMID: 3010074
-
Evidence for adenosine A2 receptor involvement in the hypomobility effects of adenosine analogues in mice.Eur J Pharmacol. 1989 Sep 22;168(3):285-90. doi: 10.1016/0014-2999(89)90789-9. Eur J Pharmacol. 1989. PMID: 2583238
-
Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys.J Pharmacol Exp Ther. 1987 Apr;241(1):76-83. J Pharmacol Exp Ther. 1987. PMID: 3572798
-
Novel therapeutics acting via purine receptors.Biochem Pharmacol. 1991 May 15;41(10):1399-410. doi: 10.1016/0006-2952(91)90555-j. Biochem Pharmacol. 1991. PMID: 2018549 Free PMC article. Review.
Cited by
-
The adenosine A2A receptor is associated with methamphetamine dependence/psychosis in the Japanese population.Behav Brain Funct. 2010 Aug 30;6:50. doi: 10.1186/1744-9081-6-50. Behav Brain Funct. 2010. PMID: 20799992 Free PMC article.
-
Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach.Mol Neurobiol. 2023 Oct;60(10):5987-6000. doi: 10.1007/s12035-023-03441-5. Epub 2023 Jun 30. Mol Neurobiol. 2023. PMID: 37391647 Review.
-
Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats.J Neurosci. 1999 Dec 15;19(24):11017-26. doi: 10.1523/JNEUROSCI.19-24-11017.1999. J Neurosci. 1999. PMID: 10594082 Free PMC article.
-
Receptor-receptor interactions as an integrative mechanism in nerve cells.Mol Neurobiol. 1993 Fall-Winter;7(3-4):293-334. doi: 10.1007/BF02769180. Mol Neurobiol. 1993. PMID: 7514001 Review.
-
Adenosine Receptor mRNA Expression in Frontal Cortical Neurons in Schizophrenia.Cells. 2023 Dec 22;13(1):32. doi: 10.3390/cells13010032. Cells. 2023. PMID: 38201235 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources